Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Iluvien fluocinolone acetonide intravitreal implant diabetic macular edema Do not reimburse Complete
Imbruvica ibrutinib Chronic graft versus host disease Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Imbruvica ibrutinib Leukemia Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Imbruvica ibrutinib Chronic lymphocytic leukemia (CLL) Reimburse with clinical criteria and/or conditions Complete
Imbruvica ibrutinib Leukemia Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Imbruvica Ibrutinib Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Reimburse with clinical criteria and/or conditions Complete
Imbruvica Ibrutinib Chronic Lymphocytic Leukemia (previously untreated) Reimburse with clinical criteria and/or conditions Complete
Imbruvica Ibrutinib Waldenstrom's Macroglobulinemia Do not reimburse Complete
Imbruvica Ibrutinib Mantle Cell Lymphoma (relapsed/refractory) Reimburse with clinical criteria and/or conditions Complete
Imbruvica ibrutinib Waldenström’s Macroglobulinemia Reimburse with clinical criteria and/or conditions Complete
Imcivree setmelanotide Bardet-Biedl syndrome Reimburse with clinical criteria and/or conditions Complete
Imdelltra tarlatamab Extensive stage small cell lung cancer Active
Imfinzi Durvalumab Unresectable Non-Small Cell Lung Cancer (NSCLC) Reimburse with clinical criteria and/or conditions Complete
Imfinzi durvalumab Extensive-stage small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Imfinzi durvalumab Biliary tract cancer Reimburse with clinical criteria and/or conditions Complete
Imfinzi durvalumab limited-stage small cell lung cancer (LS-SCLC) Received
Imfinzi durvalumab resectable non-small cell lung cancer (NSCLC) Suspended
Imfinzi durvalumab, carboplatin, paclitaxel Endometrial cancer that is mismatch repair deficient (dMMR) Active
Imfinzi and Imjudo durvalumab and tremelimumab unresectable hepatocellular carcinoma Reimburse with clinical criteria and/or conditions Complete
Imfinzi, Imjudo durvalumab, tremelimumab Metastatic non-small cell lung cancer (NSCLC) Active
Imfinzi, Lynparza durvalumab, olaparib, carboplatin, paclitaxel Endometrial cancer that is mismatch repair proficient (pMMR) Active
Imvexxy estradiol Dyspareunia Reimburse with clinical criteria and/or conditions Complete
Incivek Telaprevir Hepatitis C, chronic List with clinical criteria and/or conditions Complete
Incivek Telaprevir Hepatitis C, chronic List with criteria/condition Complete
Incivek Telaprevir Hepatitis C, chronic List with criteria/condition Complete